Administer orally at a starting dose of 2.0 µg/kg once daily. Dosage may be adjusted to effect, not to exceed 4.0 µg/kg daily. Prascend Tablets should not be crushed due to the potential for increased human exposure.
The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment.
Dosing should be titrated according to individual response to therapy to achieve the lowest effective dose. Dose titration is based on improvement in clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) and/or improvement or normalization of endocrine tests (for example, dexamethasone suppression test or endogenous ACTH test). If signs of dose intolerance develop, the dose should be decreased by half for 3 to 5 days and then titrated back up in 2 mcg/kg increments every 2 weeks until the desired effect is achieved.
Prascend Tablets are rectangular light red colored, half-scored tablets containing 1 mg pergolide, as pergolide mesylate.
Pergolide mesylate is a synthetic ergot derivative and is a potent dopamine receptor agonist. The chemical name of pergolide mesylate is 8β-[(Methylthio) methyl]-6-propylergoline monomethanesulfonate.